Navigation Links
STEMCELL Technologies Introduces a New Animal Component-Free, Serum-Free Medium for Culturing Human Mesenchymal Stem Cells

STEMCELL Technologies, Inc. today announced the release of MesenCult®-ACF Medium, the first defined, animal component-free (ACF) and serum-free medium for culturing human mesenchymal stem cells (MSCs).

Vancouver, B.C. (PRWEB) April 28, 2009 -- STEMCELL Technologies, Inc. today announced the release of MesenCult®-ACF Medium, the first defined, animal component-free (ACF) and serum-free medium for culturing human mesenchymal stem cells (MSCs).

MesenCult®-ACF Medium supports long-term growth of MSCs with retention of multi-lineage differentiation potential. In addition, MSCs cultured in MesenCult®-ACF Medium expand faster and show a significant reduction in hematopoietic cell contamination at early passages compared to serum-containing media.

"MesenCult®-ACF Medium is a very important addition to our product portfolio and indicates our strong interest in remaining at the cutting edge of scientific and preclinical work in the stem cell arena," says Dr. Allen Eaves, President and CEO of STEMCELL Technologies.

There is considerable interest in using mesenchymal stem cells as therapeutic agents for the treatment of a wide variety of diseases. Because of this clinical interest, there is a need to culture the cells in animal component-free culture systems, in order to minimize the risk associated with disease transmission and immune rejection of transplanted cells. The availability of MesenCult®-ACF Medium will greatly facilitate advances in efforts to assess the therapeutic relevance of mesenchymal stem cells.

Furthermore, the removal of undefined components within the medium reduces the variability traditionally associated with culture of these cells and allows for more consistent research and development work on this very important cell type.

For more information about MesenCult®-ACF Medium, please visit

Kristy Favell, MSc, Assistant Product Manager - Neural and Mesenchymal Cell Biology
STEMCELL Technologies Inc

About STEMCELL Technologies
STEMCELL Technologies, a privately-owned biotechnology company, is a leader in specialty cell culture media, cell separation products and ancillary reagents for life science research. Driven by science, STEMCELL delivers over 900 products to more than 70 countries worldwide. To learn more about how STEMCELL helps to make research work, visit


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Neuralstem Responds to New StemCells, Inc. Lawsuit
2. Neuralstem Sues StemCells, Inc. Over New Patent
3. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
4. China Medical Technologies Receives SFDA Approval for Its Bladder Cancer FISH Probe
5. Dr. Susan Weinschenk, Chief of Technical Staff and Services, Speaks on Neuro Web Design at Persuasive Technologies 2009 Conference and Voices That Matter Web Design Conference
6. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
7. Waters and University of Warwick Sign Research Agreement Designed to Foster Adoption of Novel MS Technologies
8. ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canadas Ability to Deal with Biological Threats
9. Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results
10. Vertebral Technologies Receives Award for InterFuse(R) Interbody Fusion System
11. Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
Post Your Comments:
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Neurocrine ... Kevin Gorman , President and CEO of Neurocrine ... Jaffray Healthcare Conference in New York ... encouraged to visit the website approximately 5 minutes prior ... software.  A replay of the presentation will be available ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
Breaking Biology News(10 mins):